Thank you Nestle we so needed the cancer causing nature identical flavouring in our everyday Filter Coffee.
How can we ever thank you enough ?!
Why would Nestle after facing such massive backlash still go ahead and put muck into their products…….. this led me into thinking maybe there is a tie up. We make the people sick so that they come to the Pharma’s to buy medicine “The Most Lucrative Business” in todays world !
Didn’t have to try too hard- Here i was with million links proudly stating how Nestle has acquired Pharma’s and will make sure you and i or us no one will remain healthy if we touched their stuff.
Food giant Nestle has continued its push into pharma with a $1.9bn partnership with Seres Therapeutics to develop drugs for inflammatory bowel disease and a common gastrointestinal infection.
The deal includes a $120m upfront payment to Massachusetts-based Seres, which focuses on developing therapies based on the manipulation of the microbiome – the population of trillions of microorganisms that live within humans.
The terms of the agreement give Nestle Health Science rights to four Seres programmes for Clostridium difficile infection (CDI) and IBD – which includes Crohn’s disease and ulcerative colitis – outside the US and Canada.
These include CDI treatments SER-109 and SER-262, and the experimental IBD drugs SER-287 and SER-301, which together account for the majority of active projects in Seres’ pipeline.
SER-109 is in phase II trials and has already shown efficacy against CDI in a phase I/II proof-of-concept study in 30 patients which revealed a 97% cure rate.
The therapy – and follow-up SER-262 – takes the form of a complex mixture of spores and bacteria that are designed to restore the normal balance of micro-organisms in the GI tract and prevent recurring CDI in patients who suffer from repeated attacks of the infection.
The FDA has granted SER-109 breakthrough status in this indication, as an off-the-shelf alternative to faecal microbiota transplants (FMT) which have shown some success in CDI trials.
CDI is the leading cause of hospital-acquired infection in the US and is responsible for the deaths of approximately 29,000 Americans each year, according to Seres. While antibiotic therapy is generally effective, it can disturb the microbiome and make recurrent CDI more likely.
SER-287 is another oral microbiome therapeutic which is currently being evaluated in a phase Ib trial involving people with mild to moderate ulcerative colitis. The principle behind the treatment is that IBD can arise from an imbalance in the gut microbiome, and restoring the normal microflora can reduce the triggers of the immune reactions that cause symptoms.
The deal with Nestle reflects the growing interest in three-year-old Seres, which was among the ranks of biopharma companies that successfully closed initial public offerings (IPOs) during 2015, raising some $140m. The company has been led by former Merck & Co executive Roger Pomerantzsince 2014.
Meanwhile, Nestle Health Science has made a series of acquisitions in the last few years as it builds what it describes as a “new industry between the traditional nutrition and pharmaceutical industries.”
In 2010 it acquired clinical nutrition company Vitaflo, following that with the purchase of chronic kidney disease specialist CM&D Pharma and GI and oncology firm Prometheus as well as taking a minority stake in Accera, a developer of therapies for neurodegenerative disorders including Alzheimer’s disease.
Nestlé is challenging the global drugs industry with plans to invest SFr500m ($510m) over the next decade to support the creation of a standalone health science business to tackle obesity and chronic disease.
The Swiss food group, which announced the move on Monday, appointed Luis Cantarell, one of its most experienced executives, to “pioneer a new industry between food and pharma” that will develop products to combat diabetes, heart problems and Alzheimer’s.